newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra
Health

Alembic Pharmaceuticals Limited announces USFDA Final Approval for Carbamazepine Tablets USP, 200 mg

Alembic Pharmaceuticals Limited announces USFDA Final Approval for Carbamazepine Tablets USP 200 mg

17th April, 2025, Bengaluru: Alembic Pharmaceuticals Limited (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Carbamazepine Tablets USP, 200 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Tegretol Tablets, 200 mg, of Novartis Pharmaceuticals Corporation. Carbamazepine Tablets USP, 200 mg are indicated for use as an anticonvulsant drug. It is also indicated in the treatment of the pain associated with true trigeminal neuralgia. Refer label for a detailed indication.

Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA.

Alembic has a cumulative total of 222 ANDA approvals (196 final approvals and 26 tentative approvals) from USFDA.

Related posts

Mohan Babu University Hosts National Conference on ‘Bridging the Gap Between Academia and Industry in Health Sciences’ with esteemed Field Dignitaries

Newsmantra

Vibcare Healthcare Opens a Pharmaceutical Manufacturing Facility with Rs 40 crore investment in Panchkula, Haryana

Newsmantra

Redcliffe Labs owned Medicentre acquires Kota’s Prime Sonography & Diagnostic Centre, strengthening its presence in Rajasthan 

Newsmantra

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More